The Stock Connect Innovative Drug ETF E Fund (159316) attracted over 23 million in net inflows yesterday, with the underlying index rising nearly 1%

I'm LongbridgeAI, I can summarize articles.

As of 10:42, the Hang Seng Stock Connect Innovative Drug Index (HSSCID) rose by 0.99%; among the top ten weighted stocks, BeiGene increased by 1.2%, CSPC Pharmaceutical Group by 1%, Akeso by 2.07%, China Biologic Products by 0.91%, Hansoh Pharmaceutical decreased by 0.06%, Sinopharm Group by 1.51%, Kelun-Biotech by 1.05%, Innovent Biologics by 1.19%, and Confo Therapeutics -B by 1.35%.

The Stock Connect Innovative Drug ETF E Fund (159316) continues to attract capital inflows, with a net capital inflow of 23.8867 million yuan in the previous trading day. As of the previous trading day, the cumulative net inflow over the past month was 1.737 billion yuan, and the cumulative net inflow over the past year was 6.843 billion yuan.

In July, cross-border licensing transactions in China's biopharmaceutical sector accelerated significantly, with 12 deals totaling $9.253 billion. AstraZeneca was the most active, reaching three major collaborations with Chia Tai Tianqing (inhalable PDE3/4 inhibitor TQC3721, total deal value $2.1 billion), CSPC Pharmaceutical Group (siRNA platform and two renal target candidate drugs, total deal value $1.77 billion), and Dizal Pharma (Surotinib, $1.5 billion), with a cumulative amount exceeding $5.37 billion.

Regarding popular companies, on August 3, China Biologic Products announced that its subsidiary, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., had its independently developed Class 1 innovative drug TQB2102 'HER2 Bispecific Antibody ADC' included in the Breakthrough Therapy List by the Center for Drug Evaluation (CDE) of the National Medical Products Administration.

A research report from Zhongtai Securities points out that in recent years, Chinese innovative drug companies have made continuous breakthroughs in fields such as ADC, bispecific antibodies, and autoimmune diseases, with some assets entering global key clinical stages. Many MNCs, after acquiring Chinese innovative drug assets, will continuously clarify their subsequent R&D positioning for Chinese innovative drugs as clinical development support work improves and their own commercial structures change. They are paying attention to the progress of subsequent Phase III clinical development of already BD products and combination opportunities with internal MNC pipelines, as well as the accumulation of subsequent clinical data and overseas clinical research application progress for un-BD products that possess scarcity and alignment with MNC pipelines.

The management fee rate for the Stock Connect Innovative Drug ETF E Fund (159316) is 0.15%, the custody fee rate is 0.05%, and the comprehensive fee rate is 0.2%. The lower fee rates can effectively reduce cost expenditures for investors.

The Stock Connect Innovative Drug ETF E Fund (159316) is currently the only ETF product tracking the Hang Seng Innovative Drug Index in the market, possessing high elasticity and scarcity, helping investors better seize investment opportunities in Hong Kong stock innovative drugs this round.